Clinical trial of tofacitinib combined with hydroxychloroquine in the treatment of patients with refractory rheumatoid arthritis
10.13699/j.cnki.1001-6821.2024.05.007
- VernacularTitle:托法替布联合羟氯喹治疗难治性类风湿关节炎患者的临床研究
- Author:
Ming-Jie WANG
1
;
Feng-Jin XU
;
Yan ZHANG
;
Yan XUE
Author Information
1. 衡水市人民医院、哈励逊国际和平医院风湿免疫科,河北衡水 053000;河北医科大学 临床学院,河北石家庄 050017
- Keywords:
tofacitinib tablet;
hydroxychloroquine tablet;
refractory rheumatoid arthritis;
disease activity;
clinical efficacy;
safety evaluation
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(5):663-667
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of tofacitinib tablets combined with hydroxychloroquine tablets in the treatment of patients with refractory rheumatoid arthritis.Methods Patients with refractory rheumatoid arthritis were randomly divided into control and treatment groups.The control group was given enteric-coated sulfasalazine tablets 1.0 g per time,three times a day,orally+methotrexate tablets 10 mg per time,once a week,orally+hydroxychloroquine sulfate tablets 0.2 g per time,twice a day,orally.The treatment group received citrate tofacitinib tablets 5 mg per time,twice a day,orally,on the basis of control group.Two groups were treated for 6 months.The clinical efficacy,disease activity,joint pain level,rheumatoid factor(RF),and adverse drug reactions were compared between the two groups.Results Treatment group was enrolled 80 cases,4 cases dropped out,and 76 cases were included in the statistical analysis.Control group was enrolled 80 cases,8 cases dropped out,and 72 cases were included in the statistical analysis.After treatment,the total effective rates of treatment and control groups were 54.05％(40 cases/76 cases)and 16.22％(12 cases/72 cases)with significant difference(P＜0.05).After treatment,the disease activity score in 28 joints scores of treatment and control groups were(2.69±0.73)and(3.32±0.84)points;the visual analog scale scores were(2.72±0.71)and(3.31±0.68)points;the RF levels were(184.61±32.14)and(201.32±30.73)U·mL-1;the differences were statistically significant(all P＜0.05).The adverse drug reactions in the treatment group were gastrointestinal reactions,mild liver damage and elevated blood pressure,while those in the control group were gastrointestinal reactions and mild liver damage.The incidences of total adverse drug reactions in the treatment and control groups were 19.74％and 29.17％without significant difference(P＞0.05).Conclusion Tofacitinib tablets combined with hydroxychloroquine tablets have a definitive clinical efficacy in the treatment of refractory rheumatoid arthritis patients,which can significantly reduce the disease activity and relieve joint pain,without increasing the incidence of adverse drug reactions.
